Table 3.
Breakdown of false negatives—all evaluable subjects
| By histology (N = 245) | By stage (N = 166) | By grade (N = 166) | ||||
|---|---|---|---|---|---|---|
| # Missed | # Missed | # Missed | ||||
| CA125 | EOC | 25 | Stage I | 26 | Serous Gr 3 | 2 |
| Non-EOC | 10 | Stage II | 5 | Other Gr 3 | 5 | |
| LMP | 24 | Stage III | 2 | Grade 2 | 11 | |
| Mets | 5 | Stage IV | 0 | Grade 1 | 11 | |
| Non OvCa | 7 | Not staged | 2 | Not graded | 6 | |
| Total | 71 | Total | 35 | Total | 35 | |
| ROMA | EOC | 16 | Stage I | 19 | Serous Gr 3 | 1 |
| Non-EOC | 7 | Stage II | 1 | Other Gr 3 | 5 | |
| LMP | 21 | Stage III | 2 | Grade 2 | 6 | |
| Mets | 3 | Stage IV | 0 | Grade 1 | 6 | |
| Non OvCa | 4 | Not staged | 1 | Not graded | 5 | |
| Total | 51 | Total | 23 | Total | 23 | |
| MIA2G | EOC | 5 | Stage I | 8 | Serous Gr 3 | 0 |
| Non-EOC | 4 | Stage II | 0 | Other Gr 3 | 1 | |
| LMP | 10 | Stage III | 0 | Grade 2 | 3 | |
| Mets | 1 | Stage IV | 0 | Grade 1 | 2 | |
| Non OvCa | 2 | Not staged | 1 | Not graded | 3 | |
| Total | 22 | Total | 9 | Total | 9 | |
CA125 high-risk cutoff: premenopausal subjects > 200 U/ml; postmenopausal subjects > 35 U/ml
ROMA high-risk cutoff: premenopausal subjects ≥ 11.4; postmenopausal subjects ≥ 29.9